Novo Nordisk rebrands as 'Novo', announces cultural reset
What it is about
Who published it, and when
1 report left out of the cascade - too little in common with the story to place
How it spread - 7 original reports
Mon, 14 September 2026
1 report- Google News - Top Stories14:24first to report
Novo Nordisk rebrands as 'Novo', announces cultural reset Reuters Novo Nordisk Slims Down Name to Novo WSJ Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy CNBC No more Nordisk as Novo goes it alone amid rebranding push Fierce Pharma Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand BioSpace
Mon, 21 September 2026
3 reports- Google News - Top Stories05:02
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs Reuters Novo shares slide as drugmaker lays out post-Wegovy growth strategy CNBC Novo Nordisk stock gets drilled on pipeline concerns -- its CEO sees this as the main problem Yahoo Finance Wegovy Maker Novo Looks to New Drugs to Combat Lilly, but Investors Are Unconvinced wsj.com Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says Reuters
- El País (Spain)08:51
La empresa afronta una creciente presión de inversores y analistas para definir una estrategia de crecimiento más allá de su fármaco estrella
- freemalaysiatoday.com22:02
Shares in the Danish weight-loss drugmaker plummeted after it unveiled plans for more than five 'multi-blockbusters' by 2030 for various ailments.
Tue, 22 September 2026
1 report- Google News - Top Stories08:53
Novo defends diversification push as CEO eyes deals beyond obesity CNBC Novo targets blockbuster-heavy 2030 but share slump signals unease finance.yahoo.com Wegovy maker Novo shares slump as management grilled on pricing, M&A Reuters Novo’s prospects beyond weight-loss drugs look surprisingly lean Financial Times Novo’s Lack of Turnaround Details Disappoints, Hitting Shares Bloomberg.com
Thu, 24 September 2026
1 report- foreignpolicyjournal.com11:24
Novo Nordisk (NYSE: NVO) shares fell sharply by nearly 8% after the company's capital markets day delivered an outlook that fell well short of investor
Mon, 28 September 2026
1 report- The Hill12:23
Novo Nordisk says its potential Wegovy successor helped patients lose more weight than Zepbound in a major clinical trial.